The safety profile of retatrutide is similar to other incretin-based therapies, with the most commonly reported adverse events being transient and mostly mild to moderate gastrointestinal symptoms, with the 4 mg starting dose group having a higher incidence than the 2 mg starting dose group
When levels are chronically low, the shift tends to be gradual rather than dramatic
To speak with a member of our legal team regarding your potential case, call (318) 219-7867 or reach out online today
Both carry direct clinical weight and actively inform treatment recommendations
That selectivity has driven interest in its use for body composition, recovery, and anti-aging purposes in adults, and, increasingly, in teenagers seeking performance or physique benefits